Governance Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-18 EDT			5-day change	1st Jan Change
4.080 ^USD	+0.74%		-1.45%	-43.41%

07-09	Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	CI
06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	CI

Executive Committee: Altimmune, Inc.

Manager

Positions heldSince

Vipin K. Garg

68 year

Chief Executive Officer	2018-11-29
President	2018-11-29

J. Rex Horton

56 year

General Counsel

Gregory Weaver

69 year

Comptroller/Controller/Auditor	2024-11-10
Director of Finance/CFO	2024-11-10

Andrew Shutterly

37 year

Comptroller/Controller/Auditor

2023-01-31

Anthony Blandin

Compliance Officer

2022-01-31

M. Harris

72 year

Chief Tech/Sci/R&D Officer

2019-09-08

Bertrand Georges

Chief Tech/Sci/R&D Officer

2015-02-28

M. Roberts

66 year

Chief Tech/Sci/R&D Officer

2012-11-30

Randy Brown

Chief Tech/Sci/R&D Officer

Composition of the Board of Directors: Altimmune, Inc.

Director

CommitteesSince

Mitchel Sayare

77 year

Chairman	2017-12-31
Independent Dir/Board Member	2010-03-31

Catherine Sohn

71 year

Compensation Committee	2011-12-31
Governance Committee	2023-03-22
Nominating Committee	2023-03-22
Governance Committee Chair	2020-12-31
Nominating Committee Chair	2020-12-31

Mack Gill

73 year

Audit Committee	2004-07-31
Governance Committee	2004-07-31
Nominating Committee	2004-07-31

Wayne Pisano

70 year

Audit Committee	2018-08-29
Governance Committee Chair	2018-08-29
Nominating Committee Chair	2018-08-29

Klaus Schafer

75 year

Audit Committee	2017-05-03
Compensation Committee

Philip Hodges

57 year

Compensation Committee	2017-05-03
Audit Committee Chair	2003-08-31

Diane Jorkasky

73 year

Compensation Committee

2020-07-10

Vipin K. Garg

68 year

Director/Board Member

2018-11-29

Teri Lawver

58 year

Director/Board Member

2025-02-23

Jerome B. Durso

57 year

Director/Board Member

2025-02-23

Latest Appointments: Altimmune, Inc.

Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026	02-27	CI
Altimmune, Inc. Announces Board Appointments	02-25	CI
Altimmune Names Greg Weaver Chief Financial Officer	11-11	MT
Altimmune, Inc. Announces That David J. Drutz Will Not Stand for Re-Election to the Board	24-08-15	CI
Altimmune CFO Richard Eisenstadt Dies	24-06-26	MT
Altimmune, Inc. Appoints Andrew Shutterly as Principal Financial Officer and Principal Accounting Officer	24-06-26	CI
Altimmune, Inc. Appoints Catherine Angell Sohn, Pharm.D. to Its Board of Directors	23-03-27	CI

More news

Former Officers and Directors: Altimmune, Inc.

Insider

Positions held

SinceUntil

David Drutz

Director/Board Member	2017-04-30	2024-09-25
Chairman	2011-09-30	2017-04-30
Independent Dir/Board Member	2009-12-31	2024-09-25

Richard Eisenstadt

Comptroller/Controller/Auditor	2021-12-30	2024-06-26
Director of Finance/CFO	2021-12-30	2024-06-26
Investor Relations Contact	2021-12-30	2024-06-26
Corporate Secretary	2021-12-30	2024-06-26

Dakshina Reddy

General Counsel

2022-03-31

2024-02-29

Kent Tapper

Comptroller/Controller/Auditor

2015-05-31

2023-01-31

Jose Ochoa

Corporate Officer/Principal

2018-07-09

2022-12-31

William Brown

Comptroller/Controller/Auditor	2018-05-07	2021-12-30
Director of Finance/CFO	2018-05-07	2021-12-30
Investor Relations Contact	2018-05-07	2021-12-30
Public Communications Contact	2018-05-07	2021-12-30
Corporate Secretary	2018-05-07	2021-12-30

Sybil Tasker

Chief Tech/Sci/R&D Officer

2017-05-03

2019-06-29

William Enright

Director/Board Member	2007-12-31	2018-11-29
Chief Executive Officer	-	2018-11-29
President	-	2018-11-29

Elizabeth Czerepak

Director of Finance/CFO	2015-03-31	2018-05-07
Corporate Secretary	2015-03-31	2018-05-07

Philip MacNeill

Director of Finance/CFO	2015-04-30	2017-05-03
Corporate Secretary	2015-04-30	2017-05-03
Treasurer	2015-04-30	2017-05-03

Derace L. Schaffer

Director/Board Member	2005-03-31	-
Independent Dir/Board Member	2005-03-31	-

Ori Solomon

General Counsel

Stacey L. Jurchison

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	18
Female	2

Of which Executive Committee

Male	9
Female	0

Of which Directors

Male	9
Female	1

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

BBB

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-06 - Q2 2025 Earnings Release (Projected)

More about the company